In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
The submission is based on data from the STEP UP and STEP UP T2D clinical trials
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70 percent of whom were on double background therapy
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
Subscribe To Our Newsletter & Stay Updated
